Andrés Esteban-Cantos

Andrés Esteban-Cantos

Auto-generated profile, based on publicly available information

Andrés Esteban-Cantos

Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2017 in Malaria Journal
Verified
Journal Article
Open access
PDF file
PBPedro J. Berzosa
Pedro J. Berzosa
AEAndrés Esteban-Cantos
Andrés Esteban-Cantos
LGLuz García
Luz García
VGVicenta González
Vicenta González
MNMarisa Navarro
Marisa Navarro
ABAgustin Benito
Agustin Benito
The emergence of drug resistance in Plasmodium falciparum has been a major contributor to the global burden of malaria. Drug resistance complicates treatment, and it is one of the most important problems in malaria control. This study assessed the level of mutations in P. falciparum genes, pfdhfr, pfdhps, pfmdr1, and pfcrt, related to resistance to different anti-malarial drugs, in the Continental Region of Equatorial Guinea, after 8 years of implementing artesunate combination therapies as the first-line treatment. A triple mutant of pfdhfr (51I/59R/108N), which conferred resistance to sulfadoxine/pyrimethamine (SP), was found in 78% of samples from rural settings; its frequency was significantly different between urban and rural settings (p = 0.007). The 164L mutation was detected for the first time in this area, in rural settings (1.4%). We also identified three classes of previously described mutants and their frequencies: the partially resistant (pfdhfr 51I/59R/108N + pfdhps 437G), found at 54% (95% CI 47.75–60.25); the fully resistant (pfdhfr 51I/59R/108N + pfdhps 437G/540E), found at 28% (95% CI 7.07–14.93); and the super resistant (pfdhfr 51I/59R/108N + pfdhps 437G/540E/581G), found at 6% (95% CI 0.48–4.32). A double mutation in pfmdr1 (86Y + 1246Y) was detected at 2% (95% CI 0.24–3.76) frequency, distributed in both urban and rural samples. A combination of single mutations in the pfmdr1 and pfcrt genes (86Y + 76T), which was related to resistance to chloroquine and amodiaquine, was detected in 22% (95% CI 16.8–27.2) of samples from the area. The high level of mutations detected in P. falciparum genes related to SP resistance could be linked to the unsuccessful withdrawal of SP treatment in this area. Drug resistance can reduce the efficacy of intermittent prophylactic treatment with SP for children under 5 years old and for pregnant women. Although a high number of mutations was detected, the efficacy of the first-line treatment, artemisinin/amodiaquine, was not affected. To avoid increases in the numbers, occurrence, and spread of mutations, and to protect the population, the Ministry of Health should ensure that health centres and hospitals are supplied with appropriate first-line treatments for malaria.

15 June 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
RMRocio Montejano
Rocio Montejano
NSNatalia Stella-Ascariz
Natalia Stella-Ascariz
SMSusana Monge
Susana Monge
JSJose Ignacio Bernardino de la Serna
Jose Ignacio Bernardino de la Serna
IPIgnacio Pérez-Valero
Ignacio Pérez-Valero
JAJosé R. Arribas
José R. Arribas
Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. A prospective cohort of human immunodeficiency virus (HIV)–infected participants with suppressed virological replication was recruited to compare whole-blood telomere length (measured by quantitative multiplex polymerase chain reaction analysis) in participants with current exposure to tenofovir disoproxil fumarate (TDF) to that in participants never exposed to TDF. A total of 172 participants were included: 67 were in the TDF group, and 105 were in the non-TDF group (75 were receiving 2 nucleosides [of whom 69 were receiving abacavir], 25 were receiving a nucleos[t]ide reverse transcriptase inhibitor [N{t}RTI]–sparing regimen, and 5 were receiving lamivudine as the only nucleoside). After 2 years, the mean blood telomere length increased significantly in the whole cohort. The TDF group had significantly smaller gains in telomere length than the non-TDF group. In the analysis restricted to participants receiving N(t)RTIs, TDF exposure was not associated with an independent negative effect. In the non-TDF group, participants treated with 2 nucleosides also had significantly smaller gains in telomere length than those receiving N(t)RTI-sparing regimens or lamivudine as the only nucleoside. In HIV-infected adults with prolonged virological suppression, treatment with TDF or abacavir was associated with smaller gains in blood telomere length after 2 years of follow-up.

3 July 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
NSNatalia Stella-Ascariz
Natalia Stella-Ascariz
RMRocio Montejano
Rocio Montejano
JRJavier Rodriguez-Centeno
Javier Rodriguez-Centeno
BABelen Alejos
Belen Alejos
CSChristine Schwimmer
Christine Schwimmer
NGNEAT 001/ ANRS 143 Study Group
NEAT 001/ ANRS 143 Study Group
Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive HIV-infected adults. We compared changes in whole-blood telomere length measured with quantitative polymerase chain reaction in 201 randomly selected participants (104 raltegravir and 97 tenofovir disoproxil fumarate/emtricitabine). We performed multivariable estimative and predictive linear regression. At week 96, participants receiving tenofovir disoproxil fumarate/emtricitabine had a statistically significant higher gain in telomere length than participants receiving raltegravir. Difference in mean telomere length change between groups (tenofovir disoproxil fumarate/emtricitabine minus raltegravir) from baseline to week 96 adjusted by baseline telomere length was 0.031 (P = .009). This difference was not significantly confounded by age, gender, known duration of HIV infection, CD4 (baseline/nadir), CD8 cells, CD4/CD8 ratio, HIV viral load (baseline/week 96), tobacco and alcohol consumption, statins, or hepatitis C. Antiretroviral-naive HIV-infected adults receiving ritonavir-boosted darunavir and tenofovir disoproxil fumarate/emtricitabine had a significant higher gain in blood telomere length than those receiving ritonavir-boosted darunavir and raltegravir, suggesting a better initial recovery from HIV-associated immunosenescence.

17 November 2020 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
DRDavid Rial-Crestelo
David Rial-Crestelo
RBRosa De Miguel Buckley
Rosa De Miguel Buckley
RMRocío Montejano
Rocío Montejano
LDLourdes Dominguez-Dominguez
Lourdes Dominguez-Dominguez
PAPaula Aranguren-Rivas
Paula Aranguren-Rivas
ASA Sotillo
A Sotillo
Background: In the ART-PRO pilot trial there were no virological failures through 48 weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and without archived lamivudine resistance-associated mutations (RAMs) detected through next-generation sequencing (NGS) but without evidence of lamivudine RAMs in baseline proviral DNA population sequencing. Objectives: To present 96 week results from ART-PRO. Methods: Open-label, single-arm pilot trial. At baseline, all participants switched to dolutegravir plus lamivudine. Participants were excluded if proviral DNA population genotyping detected lamivudine RAMs. To detect resistance minority variants, proviral DNA NGS was retrospectively performed from baseline samples. For this analysis the efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 96. Safety and tolerability outcomes were incidence of adverse events and treatment discontinuations. Results: Forty-one participants were included, 21 with lamivudine RAMs in historical plasma RNA genotypes. Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively. At 96 weeks, 90.2% of participants achieved the efficacy endpoint. Between week 48 and 96 there was one discontinuation due to consent withdrawal and no discontinuations related to adverse events. Two participants had a transient viral rebound, both re-suppressed on dolutegravir plus lamivudine. Through week 96, there were no virological failures. Conclusions: In this pilot trial, dolutegravir plus lamivudine maintained virological suppression at 96 weeks despite historical lamivudine resistance and persisting archived minority lamivudine RAMs.

1 April 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
AEAndrés Esteban-Cantos
Andrés Esteban-Cantos
BABelén Aracil
Belén Aracil
VBVerónica Bautista
Verónica Bautista
AOAdriana Ortega
Adriana Ortega
NLNoelia Lara
Noelia Lara
TNthe EuSCAPE-Spain Network
the EuSCAPE-Spain Network
We studied in parallel the population structure of 90 carbapenemase-producing and 88 carbapenemase-susceptible Klebsiella pneumoniae isolates collected in 20 Spanish hospitals, in the context of the EuSCAPE project. Fourteen and 50 multilocus sequence types (MLSTs) were detected among the carbapenemase-producing and carbapenem-susceptible isolates, respectively. ST11 and ST15 clones were more frequent in the carbapenemase-producing group than in the carbapenemase-susceptible group ( P < 0.0001). Among the members of the carbapenem-suceptible group, the cefotaxime-resistant population showed population parameters that differed between the populations of the wild-type strains and the carbapenemase producers.

18 April 2026 in eClinicalMedicine
Verified
Journal Article
Open access
CMCristina Marcelo-Calvo
Cristina Marcelo-Calvo
AEAndrés Esteban-Cantos
Andrés Esteban-Cantos
FJFrancisco Jurado
Francisco Jurado
RMRocío Montejano
Rocío Montejano
JRJavier Rodríguez-Centeno
Javier Rodríguez-Centeno
JAJosé R. Arribas
José R. Arribas
Metformin is increasingly studied as a potential geroprotective agent in the general population. We aimed to test the efficacy and safety of metformin to improve epigenetic age in older, well-controlled, non-diabetic people living with HIV. METFORAGING was a single-centre, double-blind, randomised, parallel-group, placebo-controlled pilot trial. Non-diabetic participants living with HIV who were aged 50 years or older, virologically suppressed, on a stable antiretroviral regimen with undetectable viral load for at least 12 months, and had CD4+ T-cell counts >500 cells/μL were recruited from the HIV clinic at La Paz University Hospital (Madrid, Spain). Participants were randomly assigned (1:1) to receive 850 mg oral metformin or matching placebo twice a day for 96 weeks. Participants, investigators, and outcome assessors were masked to treatment allocation. Study visits were conducted at baseline and at weeks 4, 8, 24, 48, 72, and 96. Adherence was evaluated at each visit through pill count and self-report. At baseline and week 96, whole-blood samples were used to calculate biological age across 11 epigenetic biomarkers: first-generation epigenetic clocks (Horvath’s clock and Hannum’s clock), second-generation epigenetic clocks (PhenoAge and GrimAge V2), principal component-derived epigenetic clocks (PC-Horvath, PC-Hannum, PC-PhenoAge and PC-GrimAge), a third-generation clock (DunedinPACE), and the DNA methylation-based estimator of blood telomere length (DNAmTL). The primary outcome was the adjusted between-group difference in epigenetic age acceleration (EAA) change measured by the PhenoAge clock at week 96 in the per-protocol population. Analyses were stratified by age, sex, baseline CD4 count, smoking status, statin treatment, and route of HIV transmission. The trial was registered with EudraCT, 2021-003299-15. Between March 2, and Oct 2, 2022, 55 individuals were screened, and 40 were randomly assigned to metformin (n = 19) or placebo (n = 21). Enrolment was closed at 40 participants because of slow recruitment, below the pragmatic target of 60 outlined in the study protocol. Median age was 56.4 years (IQR 53.0–60.8), 12 (30%) were female, and 35 (87.5%) self-identified as White. Mean adherence by pill count was 97.5% in both groups. 35 (87.5%) of 40 participants continued treatment to 96 weeks (n = 17 in the metformin group and n = 18 in the placebo group; per-protocol population). At week 96, the adjusted between-group difference (metformin vs. placebo) for PhenoAge EAA was −1.02 years (95% confidence interval [CI] −5.30 to 3.26; p = 0.627). 48 adverse events occurred in 16 (84%) of 19 participants who received metformin and 48 adverse events occurred in 19 (90%) of 21 participants who received placebo. In the metformin group, no serious adverse events were attributed to the medication and no deaths or hospitalisation occurred. Although no significant difference was noted in the primary outcome between groups, these preliminary findings support the feasibility of geroscience-trials in this population and support further investigation of metformin in larger, adequately powered studies to determine whether metformin can modify biological ageing in people with HIV. Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, and the European Union.